Show simple item record

dc.contributor.authorDolcet Roca, Xavier
dc.contributor.authorLlobet Navàs, David
dc.contributor.authorPallares, Judit
dc.contributor.authorRué i Monné, Montserrat
dc.contributor.authorComella i Carnicé, Joan Xavier
dc.contributor.authorMatias-Guiu, Xavier
dc.date.accessioned2016-05-24T08:02:12Z
dc.date.issued2005
dc.identifier.issn0023-6837
dc.identifier.urihttp://hdl.handle.net/10459.1/57087
dc.description.abstractThe FLICE-inhibitory protein (FLIP) plays a key role in the regulation of apoptosis triggered by death ligands. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to induce apoptosis in some types of tumor but not in others. To assess the possible role of FLIP in apoptosis resistance in endometrial carcinoma, we performed an immunohistochemical study on a tissue microarray composed of 95 endometrial carcinomas. We found positive signals in 43% of the cases, as well as a significant difference in FLIP expression between stage I and II tumors. Moreover, we observed that endometrial carcinoma cell lines Ishikawa and KLE did not undergo apoptosis after TRAIL treatment. Cotreatment of these cells with the inhibitor of transcription actinomycin D resulted in a dramatic decrease in cell viability and induced activation of caspase-8. These events coincided with downregulation of FLIP mRNA and protein. Inhibitors of caspase-8 or overexpression of FLIP completely blocked apoptosis induced by actinomycin D plus TRAIL cotreatment. More importantly, downregulation of endogenous FLIP expression by specific siRNAs sensitized endometrial carcinoma cells to TRAIL-induced apoptosis in the absence of actinomycin D. Taken together, our results suggest for the first time a critical role for FLIP in the regulation apoptosis triggered by TRAIL in endometrial carcinoma cells.ca_ES
dc.description.sponsorshipThis work was supported by Grants FISS 01/1656, FISS PI020227, SAF 2004-05250 and 2002XT00115. XD holds a postdoctoral fellowship supported by Department d’Universitats, Recerca i Societat de la Informació, Generalitat de Catalunya (2003RED0018). JP holds a research fellowship from the Fondo de Investigaciones Sanitarias, Ministerio de Sanidad y Consumo (BEFI-02/9007). The work was also supported by FIS (PI020051 and Redes de Investigación Cooperativa), Fundació La Caixa 2002 and Suport als Grups de Recerca (Generalitat de Catalunya).ca_ES
dc.language.isoengca_ES
dc.publisherNature Publishing Groupca_ES
dc.relationMIECI/PN2004-2007/SAF2004-05250
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1038/labinvest.3700286ca_ES
dc.relation.ispartofLaboratory Investigation, 2005, vol. 85, núm. 7, p. 885-894ca_ES
dc.rights(c) USCAP, Inc., 2005ca_ES
dc.subjectEndometrial carcinomaca_ES
dc.subjectFLIPca_ES
dc.subjectTRAILca_ES
dc.subjectTissue microarrayca_ES
dc.titleFLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosisca_ES
dc.typearticleca_ES
dc.identifier.idgrec008550
dc.type.versionpublishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccessca_ES
dc.identifier.doihttps://doi.org/10.1038/labinvest.3700286
dc.date.embargoEndDate10000-01-01


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record